Eli Lilly, an American pharmaceutical company, completed the investment in Aktis Oncology, a biotechnology company discovering and developing novel targeted radiopharmaceuticals to treat a broad range of solid tumors. Financial terms were not disclosed. "Our strategic collaboration with Lilly leverages Aktis' unique miniprotein radiopharmaceutical platform capabilities to address novel targets, while delivering a safe and effective clinical profile. We are pleased to partner with Lilly in efforts to increase the number of patients that can derive meaningful clinical benefit from targeted radiopharmaceuticals," Matthew Roden, Aktis Oncology President and CEO.